Company intelligence / Profile preview

Xiromed

Florham Park, New Jersey, USAxiromed.com ↗

Ownership: Private
Employees: ~70
Development stage: Other

Overview

Xiromed develops and commercializes high-quality generic pharmaceuticals in the US market. Its commercial portfolio includes more than 36 drugs across various dosage forms and therapeutic areas. The company also has a robust development pipeline, including complex generics such as buprenorphine buccal film, which is under FDA review as a bioequivalent to Belbuca® for chronic pain management.

Therapeutic areas: NeurologyWomen's HealthOther
Modalities: Small moleculePeptides
Industry: Biotech

Partnerships

IntelGenx Technologies Corp. – co-development partner for buprenorphine buccal film using VersaFilm® technologyChemo Research SL – affiliated R&D partner within Insud Pharma group

Beyond the preview

Go deeper on Xiromed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xiromed.

Explore the full profile